Why ghrelin research begins with the growth hormone secretagogue receptor
The research problem: Growth hormone release is controlled by several overlapping signals. Looking only at the pituitary is like trying to understand a sports team by watching the scoreboard without observing the players.
The solution is to examine the entire signalling pathway.
Ghrelin was discovered as the endogenous, or naturally occurring, ligand for GHS-R1a. A ligand is a molecule that binds to a receptor and changes its activity. In this case, ghrelin acts on a receptor found in key areas of the hypothalamus and anterior pituitary.
The receptor belongs to the G protein-coupled receptor (GPCR) family. GPCRs are like communication panels on the surface of cells. When the right molecular signal reaches the panel, it activates internal pathways.
For GHS-R1a, those pathways are associated with:
- Growth hormone release from pituitary somatotrophs, the specialised cells that produce growth hormone
- Hypothalamic control of growth hormone-releasing hormone, or GHRH
- Modulation of somatostatin, a hormone that can restrain growth hormone release
- Appetite and energy-balance signalling
- Broader cardiovascular, neurological and tissue-maintenance research
Ghrelin therefore does not function as a simple “on” button. It is more like a control signal entering a network of linked systems.
Short version: Ghrelin research is fundamentally receptor research.
Acylated versus unacylated ghrelin: one modification, a major difference
The research problem: Ghrelin molecules can circulate in different chemical forms. If researchers treat them as interchangeable, they may confuse two very different biological signals.
The solution is to identify the acylation state before interpreting results.
The most studied active form is acylated ghrelin (AG). It contains an eight-carbon fatty-acid group, commonly called an octanoyl group, attached to the third amino acid in the peptide chain, serine-3.
This attachment is produced by ghrelin O-acyltransferase (GOAT), an enzyme that adds the fatty-acid group to ghrelin.
Unacylated ghrelin, also called des-acyl ghrelin (UAG), lacks this fatty-acid group. It is the more abundant circulating form, while acylated ghrelin usually represents a smaller fraction of total circulating ghrelin.
Think of the acyl group as a specialised key grip. The peptide provides the general shape, but the fatty-acid modification helps the molecule fit and activate the GHS-R1a receptor effectively.
Without that modification, ghrelin’s interaction with GHS-R1a becomes extremely weak under normal physiological conditions.
Acylated vs unacylated ghrelin
| Feature | Acylated ghrelin (AG) | Unacylated/des-acyl ghrelin (UAG) |
|---|---|---|
| Chemical structure | Fatty-acid group attached to serine-3 | No fatty-acid group at serine-3 |
| Enzyme involved | GOAT adds the acyl group | Remains non-acylated or may result from deacylation |
| Circulating proportion | Usually the minor circulating form | Usually the major circulating form |
| GHS-R1a binding | High, generally in the nanomolar range | Very low, with reported activity mainly at much higher concentrations |
| Growth hormone activity | Potent growth hormone secretagogue | Little or no meaningful GHS-R1a-mediated GH release at physiological levels |
| Main research interpretation | Canonical active ghrelin signal | Distinct form with possible GHS-R1a-independent actions |
| Appetite signalling | Strongly associated with orexigenic, or appetite-stimulating, activity | Does not replicate all acylated ghrelin effects |
| Key caution | Activity depends on concentration, context and receptor biology | Should not be assumed to be an inactive “waste” form |
The important conclusion is not that unacylated ghrelin has no biological relevance. Instead, it appears to operate differently. Research has examined its possible roles in glucose regulation, cellular protection, neurobiology and tissue metabolism, including mechanisms that may not depend on GHS-R1a.
Some experimental findings also suggest that local conversion or alternative binding partners may influence UAG activity. These areas remain under investigation.
Short version: Acylation changes the message.